COO

Business profile & competitive position

The Cooper Companies, Inc. is a global medical device company headquartered in San Ramon, California, operating through two distinct segments. CooperVision develops, manufactures and markets single-use, two-week and monthly contact lenses, plus specialty eyecare products such as silicone hydrogel lenses, orthokeratology and scleral lenses. Its myopia-management franchise includes the MiSight 1 day lens. CooperSurgical supplies more than 600 products and services focused on fertility and women’s health, covering gynecology, obstetrics, contraception, labor and delivery, cord blood and tissue storage, IVF support, donor gametes, cryopreservation and genomic services. Products reach more than 130 countries, and the company reports that its products positively impact over 50 million lives annually.

From a moat perspective, the most concrete differentiator is regulatory exclusivity. MiSight 1 day is the only contact lens approved by the FDA, China’s NMPA and Japan’s MHLW to slow the progression of, and correct, myopia in age-appropriate children. That kind of tri-regulatory approval is a genuine competitive barrier and supports a specialty-lens narrative. Still, the financial returns are modest: net margin is 5.6% and ROE is 2.8%. Those figures are not what one typically associates with wide-moat, high-pricing-power healthcare businesses. Instead, they suggest a company reinvesting heavily, absorbing integration costs—especially in CooperSurgical—and competing in segments where product breadth and regulatory clearance matter more than fat margins. With a beta of 0.82, the stock also behaves more defensively than the overall market, which fits the staples-like nature of contact lenses and fertility/women’s health procedures.

Financial posture

At a market capitalization of $14.9 billion and a P/E ratio of 64.6, The Cooper Companies carries a valuation that embeds meaningful growth and margin-recovery expectations. A 64.6x multiple on current earnings is high in absolute terms and looks even more demanding against a 5.6% net margin and a 2.8% ROE. In other words, the market is not paying for today’s profitability; it is paying for a future state in which myopia-management adoption, CooperSurgical scale and operational leverage expand returns.

Risk-return framing matters here. The 5.6% net margin is thin enough that small increases in input, logistics or regulatory costs can move bottom-line results. The 2.8% ROE signals that the business is currently not generating high returns on shareholders’ equity, possibly because of acquisition-driven goodwill, capital intensity in manufacturing and distribution, and the ongoing build-out of global infrastructure. On the positive side, the beta of 0.82 implies lower systematic volatility than the broader market, which can appeal to risk-aware positioning. The current price of $76.22 sits above the 50-day EMA of $72.27, with an RSI of 60.8—neither oversold nor extremely overbought, but leaning toward the upper half of recent momentum.

Strategic priorities & outlook

The company’s most recent 10-K filing outlines a clear, operationally focused agenda. In CooperVision, management is prioritizing worldwide market penetration of recently introduced products and expanding its presence in both existing and emerging markets. That includes increasing investment in distribution and packaging capabilities to support growth and service levels. A second pillar is market development: CooperVision is investing to build the myopia-management category by educating eye-care practitioners, patients and families. That initiative ties directly to MiSight’s first-mover regulatory position and is designed to create demand rather than simply capture it.

On the CooperSurgical side, the company expects to keep investing in the business, including through strategic transactions, to expand the integrated solutions model in fertility and women’s health. The emphasis on M&A and integration suggests top-line growth is partly transaction-driven, which can create execution risk around deal synergies and balance-sheet deployment. Research-and-development spending is supported by approximately 500 R&D employees across both segments. Overall, the strategic outlook is growth-oriented but capital-intensive, which aligns with the modest current returns and high valuation multiple.

Macro & geopolitical exposure

As a Healthcare/Medical - Instruments & Supplies company, The Cooper Companies is exposed to the macro and policy currents that shape the medical-device industry. Regulatory approvals are foundational: products such as MiSight depend on FDA and foreign-regulator clearances, and any delays or labeling changes can alter revenue trajectories. Reimbursement and healthcare policy also matter; fertility services and women’s health devices are sensitive to insurance coverage decisions and government spending priorities in different geographies.

Because more than 130 countries are part of the revenue mix, currency translation is a real factor. A stronger U.S. dollar can compress reported overseas earnings, while emerging-market expansion can amplify growth when local currencies are stable. Trade policy and tariffs on medical devices, packaging materials or polymers used in lenses can affect margins, as can broader supply-chain disruptions and commodity-price swings. Demographic trends cut both ways: rising myopia rates support CooperVision’s myopia-management franchise, while fertility-rate shifts and family-planning policy changes can influence CooperSurgical demand. Product-liability and litigation risk is also inherent in any global device franchise.

Recent developments

Ticker-specific news flow in the days around August 24, 2026 is worth scanning, though some of the “COO” headlines were generated by the ticker overlapping with “chief operating officer” references at other companies. On August 23, 2026, Fool.com published “Rigetti Computing’s COO Sells Over 9,000 Company Shares. What Does That Mean for Investors?”—a story about Rigetti, not The Cooper Companies. On August 21, 2026, Zacks.com ran “COO vs. MMSI: Which Stock Is the Better Value Option?,” which directly compared the Cooper Companies’ valuation to Merit Medical Systems. On August 19, 2026, two unrelated COO-title stories appeared: GuruFocus reported Target’s second-quarter fiscal 2026 earnings call highlights, and 247WallSt.com covered Wendy’s jumping 5% on a Nelson Peltz take-private report and the revival of a COO role. The takeaway is that newswire matches for “COO” can be noisy; investors focused on The Cooper Companies should pay closest attention to the Zacks valuation comparison and, more importantly, to company-specific fundamentals rather than scattered title matches.

Earnings behavior & post-earnings drift

The Cooper Companies has delivered a perfect beat record over the last eight reported quarters, with every quarter exceeding estimates and an average earnings surprise of 4.6%. Yet the average five-trading-day move after those beats is -0.91%, classified as a “down” post-earnings drift. That pattern is unusual: beating is consistent, but the market does not reliably reward it.

The last four quarters illustrate the volatility beneath the headline beat rate. On June 4, 2026, the company reported EPS of $1.21 against a $1.10 estimate, a 10.0% surprise; the stock rose 8.58% the next day and 8.85% over the following five days. On March 5, 2026, EPS of $1.10 beat the $1.03 estimate by 6.8%, yet the stock fell 4.55% the next day and 10.82% over five days. On December 4, 2025, EPS of $1.15 beat the $1.11 estimate by 3.6%, driving a 5.67% one-day gain and a 6.59% five-day gain. On August 27, 2025, EPS of $1.10 beat the $1.07 estimate by 2.8%, but the stock dropped 12.86% the next day and 8.24% over the next five days.

This underlying volatility suggests that the market’s real expectation may run above the published consensus estimate. Even when Cooper Companies beats, forward guidance, margin commentary or segment trends can dominate the reaction. The next scheduled report is September 9, 2026 after the close, with a consensus EPS estimate of $1.12. Past beat rates do not guarantee future results, and the negative average drift is a reminder that post-earnings price action depends on far more than a one-line EPS beat.

For a deeper dive beyond the headline numbers and recent price action, investors should review the full institutional verdict on The Cooper Companies, including detailed analyst models, segment-level estimates, and the complete range of buy/hold/sell ratings.